Review Article
Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer
Table 4
Anti-EGFR mAbs monotherapy or in combination with chemotherapy for therapy naïve mCRC selected by KRAS.
| | Trial (author) |
Phase |
KRAS |
Protocol |
Number enrolled | Results |
HR (95% CI) | value | | PFS | OS |
| | Crystal (Van Cutsem et al.) [20] | III | WT | FOLFIRI + cetuximab
FOLFIRI | 172
176 | 9.9 mos.
8.7 mos. | 24.9 mos.
21.0 mos. | PFS: 0.68 (0.50–0.94)
OS: 0.84 (0.64–1.11) | 0.07
NR | | MUT | FOLFIRI + cetuximab
FOLFIRI | 105
87 | 7.6 mos.
8.1 mos. | 17.5 mos.
17.7 mos. | PFS: 1.07 (0.71–1.61)
OS: 1.03 (0.74–1.44) | 0.44
NR |
| | OPUS (Bokemeyer et al.) [21] | II | WT | FOLFOX + cetuximab
FOLFOX | 61
73 | 7.7 mos.
7.2 mos. | | PFS: 0.57 (0.35–0.90) | 0.0163 | | MUT | FOLFOX + cetuximab
FOLFOX | 52
47 | 5.5 mos.
8.6 mos. | | PFS: 1.83 (1.09–3.05) | 0.192 |
| | PRIME (Douillard et al.) [22] | III | WT | FOLFOX + panitumumab
FOLFOX | 325
331 | 9.6 mos.
8.0 mos. | 23.9 mos.
19.7 mos. | PFS: 0.80 (0.66–0.97)
OS: 0.83 (0.67–1.01) | 0.02
0.072 | | MUT | FOLFOX + panitumumab
FOLFOX | 221
219 | 7.3 mos.
8.8 mos. | 15.5 mos.
19.3 mos. | PFS: 1.29 (1.04–1.62)
OS: 1.24 (0.98–1.57) | 0.02
0.68 |
|
|
WT: wild type, MUT: mutated, PFS: progression free survival, OS: overall survival, and NR: not reported.
|
